Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”), today announces the expansion of the management team with the appointment of Mr. John P. Gargiulo, former North America President and CEO of Daiichi Sankyo, as Chief Business Officer. Mr. John P. Gargiulo will lead Ascletis’ corporate business development and alliance management in this new role and report to Dr. Jinzi J. Wu, Ph.D., Founder, Chairman, and CEO of Ascletis.
Mr. John P. Gargiulo has over 30 years of successful experience in marketing strategies, business integration, and commercial operations in the global pharma/biotech industry. He has held various senior positions with increasing responsibility for 18 years at Daiichi Sankyo, where he made a transformative contribution in driving Daiichi Sankyo’s U.S. business from the very beginning to an established pharma when he served as North America President and CEO of Daiichi Sankyo.
“John is a veteran in our industry. His proven track record in business development and commercial operation will further strengthen our management team. We are very excited to have him on board as Ascletis is advancing in the frontiers with a focus on viral diseases, NASH/PBC, and oncology. Together with the collaborations we already built globally, this new appointment will further accelerate Ascletis’ next stage of growth as we expect to launch multiple commercial products in the next three years,” said Dr. Jinzi J. Wu, Ph.D., Founder, Chairman, and CEO of Ascletis.
“Ascletis has achieved impressive growth under the leadership of Dr. Jinzi J. Wu. I’m very glad to join the management team, and expect to maximize the value of Ascletis through its robust pipeline and more strategic collaborations,” said Mr. John P. Gargiulo, Chief Business Officer of Ascletis.
Mr. John P. Gargiulo earned an MBA Degree and graduated as a Fuqua Scholar from Fuqua School of Business, Duke University. He graduated Magna cum Laude from Boston College with a Bachelor’s Degree in Economics.
